	Application No.	Applicant(s)
	09/523,102	SI ET AL.
Notice of Allowability	Examiner	Art Unit
	Sandra Saucier	1651
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to interview of 4/14/06 and amendments submitted 5/17/06.		
2. The allowed claim(s) is/are <u>1-3,5,6,71-87,89,102-106,108,109 and 111-123</u> .		
 3. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) ☐ All b) ☐ Some* c) ☐ None of the: 		
 Certified copies of the priority documents have been received. 		
2. Certified copies of the priority documents have been received in Application No		
3. Copies of the certified copies of the priority documents have been received in this national stage application from the		
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.		
(a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached		
1) hereto or 2) to Paper No./Mail Date		
(b) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s) 1. Notice of References Cited (PTO-892)	5 Notice of Informal P	ratent Application (PTO-152)
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	6. ☑ Interview Summary	
	Paper No./Mail Dat	te <u>4/14/06</u> .
 Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date 	8), 7. Examiner's Amendr	ment/Comment
Examiner's Comment Regarding Requirement for Deposit of Biological Material	8. X Examiner's Stateme	ent of Reasons for Allowance
c. Diological Material	9.	

Application/Control Number: 09/523,102

Art Unit: 1651

REASONS FOR ALLOWANCE

The following is an examiner's statement of reasons for allowance: The anticipatory prior art rejection over US 5,767,153 has been overcome by the instant claims because the instant claims are directed to inhibiting retinal neovascularization in a clearly defined a group which is in need of administration of the composition of claim 78 or 102, which group is distinct from the group as inferred in US 5,767,153. Thus, the anticipatory rejection has been overcome.

The obviousness rejection over WO 97/41844 in view of US 5,67,153 has been overcome by the instant claims because the instant claims are directed to the use of a single therapeutic neovascularization inhibitory agent of formula (I) to treat retinal neovascularization, while WO 97/41844 teaches the use of two or more agents together. Thus, the use of only one agent of formula (I) to successfully achieve treatment and inhibition of retinal neovascularization is unexpected.

Therefore, the prior art of record neither anticipates nor fairly makes obvious the instantly claimed methods.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance." Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sandra Saucier whose telephone number is (571) 272–0922. The examiner can normally be reached on Monday, Tuesday, Wednesday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, M. Wityshyn can be reached on (571) 272-0926. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 09/523,102 Page 3

Art Unit: 1651

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Sandra Saucier Primary Examiner Art Unit 1651

June 14, 2006